Skip to main content
Year archive

Vivesto — 2017 filings

All 81 regulatory filings released by Vivesto (VIVE) in 2017, sourced directly from the official regulator.

81 Filings
2017 Period
2017 filings (81)
Filing Released Lang
Oasmia Pharmaceutical receives marketing approval for Paclical® in Kazakhstan
Regulatory Filings
2017-12-11 English
Oasmia har erhållit marknadsgodkännande för Paclical® i Kazakstan
Regulatory Filings
2017-12-11 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report H1 2018
2017-12-01 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report H1 2018
2017-12-01 English
Oasmia har genomfört en riktad emission av konvertibler om totalt 28 000 000 kronor
Capital/Financing Update
2017-11-30 Swedish
Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 28,000,000
Share Issue/Capital Change
2017-11-30 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-11-15 English
Oasmia Pharmaceutical ABs CFO lämnar bolaget
Board/Management Information
2017-10-04 Swedish
Oasmia Pharmaceutical AB Announces Resignation of its Chief Financial Officer
Board/Management Information
2017-10-04 English
Nexttobe Extends Loan to Oasmia Pharmaceutical
Capital/Financing Update
2017-10-02 English
Nexttobe förlänger lån till Oasmia Pharmaceutical
Capital/Financing Update
2017-10-02 Swedish
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2017-09-29 English
Ändring av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2017-09-29 Swedish
Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2017
AGM Information
2017-09-25 English
Årsstämma i Oasmia Pharmaceutical AB (publ) den 25 september 2017
AGM Information
2017-09-25 Swedish
Supplementary proposals of the Nomination Committee for the 2017 Annual General Meeting
AGM Information
2017-09-21 English
Valberedningens kompletterande förslag inför årsstämman 2017
AGM Information
2017-09-21 Swedish
Notification from Oasmia Pharmaceutical AB
Regulatory Filings
2017-09-11 English
Notis från Oasmia Pharmaceutical AB
Regulatory Filings
2017-09-11 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Q2 2017
2017-09-01 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Q1 2017
2017-09-01 English
Ändring av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2017-08-31 Swedish
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2017-08-31 English
KALLELSE TILL ÅRSSTÄMMA I OASMIA PHARMACEUTICAL AB
AGM Information
2017-08-25 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB
AGM Information
2017-08-25 English
Oasmia Pharmaceutical har erhållit marknadsföringstillstånd för cancerläkemedlet Doxophos® i Ryssland
Regulatory Filings
2017-08-08 Swedish
Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in Russia
Regulatory Filings
2017-08-08 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-08-02 English
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2017-07-31 English
Ändring av antalet aktier och röster i Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2017-07-31 Swedish
Oasmia Pharmaceutical AB (publ) offentliggör utfall av företrädesemissionen
Share Issue/Capital Change
2017-07-07 Swedish
Oasmia Pharmaceutical AB (publ) announces result of the rights issue
Share Issue/Capital Change
2017-07-07 English
Annual Report 2017
Annual Report FY 2017
2017-07-07 Swedish
Annual Report 2017
Annual Report FY 2017
2017-07-07 English
Utgivande av teckningsoptioner i Oasmia Pharmaceutical (publ)
Share Issue/Capital Change
2017-06-21 Swedish
Issuance of warrants in Oasmia Pharmaceutical AB (publ)
Remuneration Information
2017-06-21 English
Oasmia Pharmaceutical AB (publ) offentliggör prospekt med anledning av Företrädesemissionen
Capital/Financing Update
2017-06-19 Swedish
Oasmia Pharmaceutical AB (publ) publishes prospectus by reason of the Rights Issue
Share Issue/Capital Change
2017-06-19 English
Oasmia ingår nytt exklusivt marknadsförings- och distributionsavtal avseende Ryssland och CIS
Regulatory Filings
2017-06-14 Swedish
Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets
Regulatory Filings
2017-06-14 English
Oasmia Pharmaceutical AB (publ): The board of directors resolves upon a rights issue of approximately 163.9 MSEK
Share Issue/Capital Change
2017-06-12 English
Oasmia Pharmaceutical AB (publ): Styrelsen beslutar om företrädesemission om cirka 163,9 MSEK
Share Issue/Capital Change
2017-06-12 Swedish
Oasmia Pharmaceutical AB (publ) ersätter befintligt konvertibellån med nya skuldförbindelser
Capital/Financing Update
2017-06-08 Swedish
Oasmia Pharmaceutical AB (publ) replaces current convertible loan with new debt
Capital/Financing Update
2017-06-08 English
Interim / Quarterly Report 2017
Interim / Quarterly Report Q4 2017
2017-06-08 Swedish
Audit Report / Information 2017
Audit Report / Information FY 2017
2017-06-08 English
Report from extra general meeting 2 June 2017
AGM Information
2017-06-02 English
Kommuniké från extra bolagsstämma den 2 juni 2017
AGM Information
2017-06-02 Swedish
Antal aktier och röster i Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2017-05-31 Swedish
Number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change
2017-05-31 English
Oasmia Pharmaceutical Issues Clarification Regarding Clinical Study OAS-12DOC-BIO
Legal Proceedings Report
2017-05-29 English
Oasmia Pharmaceutical förtydligar angående studie OAS-12DOC-BIO
Regulatory Filings
2017-05-29 Swedish
Oasmia Pharmaceutical bjuder in till kapitalmarknadsdag 15 juni i Stockholm
Report Publication Announcement
2017-05-23 Swedish
Oasmia Pharmaceutical Invites Shareholders to Capital Markets Day in Stockolm on June 15th
Report Publication Announcement
2017-05-23 English
Oasmia convenes an extraordinary general meeting on the 2 June, 2017
AGM Information
2017-05-10 English
Oasmia kallar till extra bolagsstämma 2 juni 2017
AGM Information
2017-05-10 Swedish
Ökat antal aktier och röster i Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2017-05-01 Swedish
Increased number of shares and votes in Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2017-05-01 English
Conversion of SEK 42M convertible loan in Oasmia
Capital/Financing Update
2017-04-25 English
Konvertering av konvertibellån om 42 miljoner kronor i Oasmia
Share Issue/Capital Change
2017-04-25 Swedish
Oasmia completes set-off private placements of new convertibles in the total amount of SEK 26 million with conversion rate of SEK 8.00
Capital/Financing Update
2017-04-18 English
Oasmia genomför riktad kvittningsemission av konvertibler om totalt 26 miljoner kr med konverteringskurs om 8,00 kr
Capital/Financing Update
2017-04-18 Swedish
Oasmia genomför riktad emission av konvertibler om totalt 42 miljoner kr med konverteringskurs om 5,95 kr
Capital/Financing Update
2017-03-31 Swedish
Oasmia successfully completes private placements of new convertibles in the total amount of SEK 42 million with conversion rate of SEK 5.95
Capital/Financing Update
2017-03-31 English
Oasmia evaluates the possibility to carry out a private placement of new convertible instruments
Capital/Financing Update
2017-03-30 English
Oasmia undersöker förutsättningarna för att genomföra en placering av nya konvertibler
Capital/Financing Update
2017-03-30 Swedish
Major Shareholding Notification 2017
Major Shareholding Notification
2017-03-23 English
Oasmia avser emittera ny konvertibel för att ersätta befintligt konvertibellån
Capital/Financing Update
2017-03-21 Swedish
Oasmia intends to issue convertible to replace current convertible loan
Capital/Financing Update
2017-03-21 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-03-08 English
Interim / Quarterly Report 2017
Interim / Quarterly Report 9M 2017
2017-03-03 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report 9M 2017
2017-03-03 English
Tydliggörande från styrelse, ledning samt huvudägare i Oasmia Pharmaceutical AB (publ) med anledning av Anders Lönners utträde ur bolagets styrelse
Board/Management Information
2017-03-01 Swedish
Clarification from the Board of Directors, Company Management and the Principal Shareholders of Oasmia Pharmaceutical AB (publ) Surrounding Anders Lönner’s Withdrawal from the Board of Directors
Board/Management Information
2017-03-01 English
Oasmia Pharmaceuticals Chairman Anders Lönner Resigns
Board/Management Information
2017-02-28 English
Oasmia Pharmaceuticals styrelseordförande Anders Lönner avgår
Board/Management Information
2017-02-28 Swedish
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements
2017-01-31 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-01-27 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-01-25 English
Oasmia Pharmaceutical aviserar strategiska åtgärder för att stärka sin position inom veterinärmedicin
Regulatory Filings
2017-01-23 Swedish
Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division
Regulatory Filings
2017-01-23 English